Study record

Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator

Wang P, Tao W, Wen H et al. · Front Immunol · 2026

AnalyticalMOTS-c administeredEvidence tier D

What this study reported

Reported that an Ms4a6c-expressing macrophage subpopulation was associated with pro-fibrotic programmes in a murine radiation proctitis model and in human liver cirrhosis and pulmonary fibrosis datasets. Reported that molecular docking and dynamics simulations ranked MOTS-c as a top candidate predicted to bind Ms4a6c, with no experimental testing of MOTS-c.

Limitations

MOTS-c involvement is entirely computational, with no binding assay or in vivo testing; the authors state experimental validation is pending; single murine model underlies the primary transcriptomics.

Study record

Annotated fields for this study
Study modelAnalytical / methods
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Speciesmouse, human
System studiedBulk and single-cell transcriptomics of a murine chronic radiation proctitis model with virtual screening and molecular dynamics
PopulationNot reported
DesignComputational and transcriptomic analysis
Sample size as reportednot reported
Control groupnon-irradiated model comparison and independent human single-cell datasets
Route (data field only)Not reported
Endpoints measuredMs4a6c-expressing macrophage subpopulation; Thbs1-Cd47 and Cebpb regulon inference; cross-disease fibrosis signatures; virtual knockout simulation; molecular docking ranking
Pathways measuredInflammation · TGF-β / SMAD
Research areasInflammation & immunity · Methods
Evidence tierD — Cell, tissue or analytical
Publication typesJournal Article, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Indirect
Model applicability
n/a
Sample size
Not reported
Controls
Limited
Outcome validity
Exploratory
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.